natgillin/translations-raw huggingface dataset:
Import duties should be fixed for the period from 1 May 2010 and should apply until new import duties are fixed and enter into force,
Uvozne dajatve, ki se uporabljajo, dokler ne začne veljati nova določitev, se določijo za obdobje z začetkom 1. maja 2010 –
From 1 May 2010, the import duties in the cereals sector referred to in Article 136(1) of Regulation (EC) No 1234/2007 shall be those fixed in Annex I to this Regulation on the basis of the information contained in Annex II.
Od 1. maja 2010 so uvozne dajatve v sektorju žit iz člena 136(1) Uredbe (ES) št. 1234/2007 dajatve, določene v Prilogi I k tej uredbi na podlagi podatkov, navedenih v Prilogi II.
Import duties on the products referred to in Article 136(1) of Regulation (EC) No 1234/2007 applicable from 1 May 2010
Uvozne dajatve za proizvode iz člena 136(1) Uredbe (ES) št. 1234/2007, ki se uporabljajo od 1. maja 2010
Commission Regulation (EU) No 375/2010
Uredba Komisije (EU) št. 375/2010
of 3 May 2010
z dne 3. maja 2010
Following an application from PROBI AB, submitted on 22 December 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactobacillus plantarum 299v on improved iron absorption (Question No EFSA-Q-2008-785) [2].
Družba PROBI AB je 22. decembra 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Lactobacillus plantarum 299v na izboljšano absorpcijo železa (vprašanje št. EFSA-Q-2008-785) [2].
The claim proposed by the applicant was worded as follows: ‘Lactobacillus plantarum 299v (DSM 9843) improves iron absorption’.
Vlagatelj je predlagal naslednjo trditev: „Lactobacillus plantarum 299v (DSM 9843) izboljša absorpcijo železa“.
On 6 April 2009, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Lactobacillus plantarum 299v (DSM 9843) and the claimed effect.
Komisija in države članice so 6. aprila 2009 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Lactobacillus plantarum 299v (DSM 9843) in navedeno trditvijo ni utemeljena.
Health claims referred to in Article 13(1)(a) of Regulation (EC) No 1924/2006 are subject to the transition measures laid down in Article 28(5) of that Regulation only if they comply with the conditions therein mentioned, among which that they have to comply with the Regulation.
Zdravstvene trditve iz člena (13)(1)(a) Uredbe (ES) št. 1924/2006 so predmet prehodnih ukrepov iz člena 28(5) navedene uredbe le, če izpolnjujejo pogoje, navedene v tej uredbi, med katerimi je ta, da morajo biti v skladu z Uredbo.
As the Authority concluded that a cause and effect relationship had not been established between the consumption of Lactobacillus plantarum 299v (DSM 9843) and the claimed effect, the claim does not comply with Regulation (EC) No 1924/2006, and therefore the transition period foreseen in Article 28(5) of that Regulation is not applicable.
Ker je Agencija ugotovila, da vzročno-posledična povezava med uživanjem Lactobacillus plantarum 299v (DSM 9843) in navedeno trditvijo ni utemeljena, navedena trditev ni v skladu z Uredbo (ES) št. 1924/2006, zato se prehodno obdobje iz člena 28(5) navedene uredbe ne uporablja.
A transition period of six months is provided for, to enable food business operators to adapt to the requirements laid down in this Regulation.
Določeno je šestmesečno prehodno obdobje, da se nosilci živilske dejavnosti lahko prilagodijo zahtevam iz te uredbe.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health and neither the European Parliament nor the Council have opposed them,
Ukrepi, predvideni s to uredbo, so v skladu z mnenjem Stalnega odbora za prehranjevalno verigo in zdravje živali, Evropski parlament in Svet pa mu nista nasprotovala –
Done at Brussels, 3 May 2010.
V Bruslju, 3. maja 2010
The EFSA Journal (2009) 999, 1-9.
The EFSA Journal (2009) 999, str. 1–9.
Rejected health claims
Zavrnjene zdravstvene trditve
Lactobacillus plantarum 299v (DSM 9843) improves iron absorption
Lactobacillus plantarum 299v (DSM 9843) izboljša absorpcijo železa.
Commission Regulation (EU) No 376/2010
Uredba Komisije (EU) št. 376/2010
amending Regulation (EC) No 983/2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health
o spremembi Uredbe (ES) št. 983/2009 o odobritvi in zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, ki se nanašajo na zmanjšanje tveganja za bolezni ter na razvoj in zdravje otrok
Pursuant to Article 16(4) of Regulation (EC) No 1924/2006, an opinion of the European Food Safety Authority (EFSA), hereinafter referred to as the Authority, in favour of authorising a health claim should include certain particulars.
Mnenje Evropske agencije za varnost hrane (EFSA) (v nadaljnjem besedilu: Agencija), ki podpira odobritev zdravstvene trditve, mora v skladu s členom 16(4) Uredbe (ES) št. 1924/2006 vključevati nekatere podatke.
Accordingly, those particulars should be set out in the Annex of authorised claims to the Regulations authorising and/or refusing to authorise certain health claims made on foods and include, as the case may be, the revised wording of the claim, specific conditions of use of the claim, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
Navedeni podatki morajo biti določeni v prilogi o odobrenih trditvah k uredbam o odobritvi in/ali zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, in vsebovati, odvisno od primera, spremenjeno besedilo trditve, posebne pogoje uporabe trditve in, po potrebi, pogoje ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo v skladu s predpisi iz Uredbe (ES) št. 1924/2006 in mnenji Agencije.
Following two opinions of the Authority on plant stanols and plant sterols and lowering/reducing blood LDL-cholesterol (Question No EFSA-Q-2008-085 and Question No EFSA-Q-2008-118) [2], the Commission authorised the health claims stating that plant sterols/plant stanol esters ‘have been shown to lower/reduce blood cholesterol.
Na podlagi dveh mnenj Agencije v zvezi z estri rastlinskih stanolov in rastlinskimi steroli ter zniževanjem LDL-holesterola v krvi (vprašanje št. EFSA-Q-2008-085 in vprašanje št. EFSA-Q-2008-118) [2] je Komisija v Uredbi (ES) št. 983/2009 [3] odobrila zdravstveni trditvi, da rastlinski steroli/estri rastlinskih stanolov „dokazano bistveno znižujejo holesterol v krvi.
High cholesterol is a risk factor in the development of coronary heart disease’ in Regulation (EC) No 983/2009 [3] with the specific conditions of use of ‘Information to the consumer that the beneficial effect is obtained with a daily intake of at least 2 g of plant sterols/plant stanols’.
Povišan holesterol je dejavnik tveganja za razvoj koronarne bolezni srca“ ob posebnem pogoju, da se uporablja s posebno navedbo pogoja uporabe „Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom vsaj dveh gramov (2 g) rastlinskih sterolov/rastlinskih stanolov“.
In the context of the procedure for the authorisation of health claims under Regulation (EC) No 1924/2006, the Standing Committee on the Food Chain and Animal Health, at its meeting of 20 February 2009, concluded that, regarding the indication of a quantitative effect in health claims there was a need for scientific advice from the Authority to ensure that such health claims are authorised in a way which will not mislead the consumer, and that conditions of use are set in a coherent way.
V okviru postopka za odobritev zdravstvenih trditev v skladu z Uredbo (ES) št. 1924/2006 je Stalni odbor za prehranjevalno verigo in zdravje živali na sestanku 20. februarja 2009 sklenil, da je glede navedbe kvantitativnega učinka v zdravstvenih trditvah potrebno znanstveno svetovanje Agencije, da se zagotovi odobritev zdravstvenih trditev na način, ki ne bo zavedel potrošnika, in da so pogoji uporabe usklajeni.
To that end, the Commission submitted a request for advice to the Authority, in accordance with Article 19(2) of that Regulation.
V ta namen je Komisija Agenciji predložila zahtevo za svetovanje v skladu s členom 19(2) navedene uredbe.
On 3 August 2009 the Commission and the Member States received the scientific opinion from the Authority (Question No EFSA-Q-2009-00530 and EFSA-Q-2009-00718) [4] which concluded that for a daily intake of 1,5-2,4 g plant sterols/stanols added to foods such as yellow fat spreads, dairy products, mayonnaise and salad dressings an average reduction of between 7 and 10,5 % can be expected and that such reduction is of biological significance.
Komisija in države članice so 3. avgusta 2009 prejele znanstveno mnenje Agencije (vprašanje št. EFSA-Q-2009-00530 in EFSA-Q-2009-00718) [4], ki je sklenila, da se pri dnevnem vnosu 1,5–2,4 g rastlinskih sterolov/stanolov, dodanih živilom, kot so rumeni maščobni namazi, mlečni izdelki, majoneza in solatni prelivi, lahko pričakuje povprečno znižanje med 7 in 10,5 % ter da je tako znižanje biološko pomembno.
In addition, the Authority indicated that the blood LDL cholesterol lowering effect is usually established within the 2-3 weeks and can be sustained by a continued consumption of plant sterols/stanols.
Poleg tega je Agencija navedla, da se učinek znižanega LDL-holesterola v krvi ponavadi pojavi v 2 do 3 tednih in se lahko ohrani s stalnim uživanjem rastlinskih sterolov/stanolov.
Therefore, taking into account the scientific opinion from the Authority and in order to ensure that such health claims referring to the magnitude of the claimed effect are authorised in a way that would not mislead the consumer, and that their conditions of use are set in a coherent way, it is necessary to amend the conditions of use set for the two authorised health claims related to the effects of plant sterols and plant stanol esters on the lowering of the blood cholesterol.
Zato je ob upoštevanju znanstvenega mnenja Agencije in z namenom zagotovitve odobritev takih zdravstvenih trditev, ki se nanašajo na stopnjo učinka navedene trditve, na način, da ne zavajajo potrošnika ter da so pogoji uporabe usklajeni, treba spremeniti pogoje uporabe, določene za dve odobreni zdravstveni trditvi v zvezi z učinki rastlinskih sterolov in estrov rastlinskih stanolov na znižanje holesterola v krvi.
Following the opinion of the Authority on essential fatty acids and in particular α-linolenic acid (ALA) and linoleic acid (LA) and normal growth and development of children (Question No EFSA-Q-2008-079) [5], the Commission, authorised the health claim ‘Essential fatty acids are needed for normal growth and development of children’ in Regulation (EC) No 983/2009 with the specific conditions of use of ‘Information to the consumer that the beneficial effect is obtained with a daily intake of 1 % of total energy for linoleic acid and 0,2 % of total energy for α-linolenic acid’.
Komisija je na podlagi mnenja Agencije o esencialnih maščobnih kislinah in zlasti α-linolenski kislini (ALA) in linolni kislini (LA) ter normalni rasti in razvoju otrok (vprašanje št. EFSA-Q-2008-079) [5] odobrila zdravstveno trditev „Esencialne maščobne kisline so potrebne za normalno rast in razvoj otrok“ v Uredbi (ES) št. 983/2009 ob posebnem pogoju uporabe „Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom linolne kisline, ki predstavlja 1 % celotnega energijskega vnosa, in dnevnim vnosom α-linolenske kisline, ki predstavlja 0,2 % celotnega energijskega vnosa“.
In the context of the procedure for the authorisation of health claims under Regulation (EC) No 1924/2006, the Standing Committee on the Food Chain and Animal Health, at its meeting of 20 February 2009, concluded that the Authority should be asked to give general advice on reference values for the purpose of labelling for fatty acids to enable the review of the conditions of use for the relevant authorised health claim, in accordance with Article 19(2) of that Regulation.
V okviru postopka za odobritev zdravstvenih trditev v skladu z Uredbo (ES) št. 1924/2006 je Stalni odbor za prehranjevalno verigo in zdravje živali na sestanku 20. februarja 2009 sklenil, da je treba Agencijo zaprositi za splošno svetovanje o referenčnih vrednostih za označevanje maščobnih kislin, da se v skladu s členom 19(2) navedene uredbe omogoči pregled pogojev uporabe za ustrezno odobreno zdravstveno trditev.
On 3 August 2009 the Commission and the Member States received the scientific opinion from the Authority (Question No EFSA-Q-2009-00548) [6] which concluded that the proposed labelling reference value of 2 g for the n-3 polyunsaturated fatty acid (PUFA) ALA is consistent with the recommended intakes for individuals in the general population in European countries.
Komisija in države članice so 3. avgusta 2009 prejele znanstveno mnenje Agencije (vprašanje št. EFSA-Q-2009-00548) [6], ki je sklenila, da je predlagana referenčna vrednost 2 g za označbo n-3 polinenasičene maščobne kisline (PUFA) ALA v skladu s priporočenimi vnosi za posameznika v splošni populaciji evropskih držav.
In addition, the Authority proposed 10 g as labelling reference intake value for n-6 PUFA LA.
Poleg tega je Agencija predlagala 10 g kot referenčno vrednost vnosa za označbo n-6 PUFA LA.
Therefore, taking into account the scientific opinion from the Authority and in order to set appropriate conditions of use for the health claims related to the effects of fatty acids, it is necessary to amend the conditions of use set for the authorised health claim related to the effects of essential fatty acids on normal growth and development of children.
Zato je ob upoštevanju znanstvenega mnenja Agencije in z namenom, da se določi ustrezne pogoje uporabe za zdravstvene trditve v zvezi z učinki maščobnih kislin, potrebno spremeniti pogoje uporabe, določene za odobrene zdravstvene trditve v zvezi z vplivi esencialnih maščobnih kislin na normalno rast in razvoj otrok.
In Annex I to Regulation (EC) No 983/2009, the table is amended as follows:
Preglednica v Prilogi I k Uredbi (ES) št. 983/2009 se spremeni:
the text of the first entry, fifth column (Conditions of use of the claim), is replaced by the following:
besedilo v petem stolpcu prvega vnosa (Pogoji uporabe trditve) se nadomesti z naslednjim:
‘Information to the consumer that the beneficial effect is obtained with a daily intake of 1,5-2,4 g plant sterols.
„Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom 1,5–2,4 g rastlinskih sterolov.
Reference to the magnitude of the effect may only be made for foods within the following categories: yellow fat spreads, dairy products, mayonnaise and salad dressings.
Sklicevanje na moč učinka se lahko uporablja samo na živilih iz sledečih kategorij: rumeni maščobni namazi, mlečni izdelki, majoneza in solatni prelivi.
When referring to the magnitude of the effect, the entire range “7 to 10 %” and the duration to obtain the effect “in 2 to 3 weeks” must be communicated to the consumer.’;
Ko se informacija nanaša na moč učinka, mora biti potrošnik obveščen o celotnem obsegu ‚7 do 10 %‘ in času ‚v 2 do 3 tednih‘, v katerem se doseže učinek.“;
the text of the second entry, fifth column (Conditions of use of the claim), is replaced by the following:
besedilo v petem stolpcu drugega vnosa (Pogoji uporabe trditve) se nadomesti z naslednjim:
‘Information to the consumer that the beneficial effect is obtained with a daily intake of 1,5-2,4 g plant stanols.
„Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom 1,5–2,4 g rastlinskih stanolov.
the text of the third entry, fifth column (Conditions of use of the claim), is replaced by the following:
besedilo v petem stolpcu tretjega vnosa (Pogoji uporabe trditve) se nadomesti z naslednjim:
‘Information to the consumer that the beneficial effect is obtained with a daily intake of 2 g of α-linolenic acid (ALA) and a daily intake of 10 g of linoleic acid (LA)’.
„Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom 2 g α-linolenske kisline (ALA) in z dnevnim vnosom 10 g linolne kisline (LA)“.
The EFSA Journal (2008) 781, 1-2 and 825, 1-13 respectively.
The EFSA Journal, (2008) 781, str. 1–2, in 825, str. 1–13.
The EFSA Journal (2009) 1175, 1-9.
The EFSA Journal, (2009) 1175, str. 1–9.
The EFSA Journal (2008) 783, 1-10.
The EFSA Journal, (2008) 783, str. 1–10.
The EFSA Journal (2009) 1176, 1-11.
The EFSA Journal, (2009) 1176, str. 1–11.
Corrigendum to Commission Directive 2010/89/EU of 6 November 2010 amending Council Directive 91/414/EEC to include quinmerac as active substance and amending Decision 2008/934/EC
Popravek Direktive Komisije 2010/89/EU z dne 6. novembra 2010 o spremembi Direktive Sveta 91/414/EGS zaradi vključitve kvinmeraka kot aktivne snovi in o spremembi Odločbe 2008/934/ES
(Official Journal of the European Union L 320 of 7 December 2010)
(Uradni list Evropske unije L 320 z dne 7. decembra 2010)
In the title on the cover page and on page 3, and in the signature on page 5:
V naslovu v kazalu na naslovni ovitka, naslovu na strani 3 ter v podpisu na strani 5:
‘6 November 2010’,
„6. november 2010“
‘6 December 2010’.
„6. december 2010“.
Commission Regulation (EU) No 377/2010
Uredba Komisije (EU) št. 377/2010
imposing a provisional anti-dumping duty on imports of sodium gluconate originating in the People’s Republic of China
o uvedbi protidampinške dajatve na uvoz natrijevega glukonata s poreklom iz Ljudske republike Kitajske
Having regard to Council Regulation (EC) No 1225/2009 of 30 November 2009 on protection against dumped imports from countries not members of the European Community [1] (the basic Regulation), and in particular Article 7 thereof,
ob upoštevanju Uredbe Sveta (ES) št. 1225/2009 z dne 30. novembra 2009 o zaščiti proti dampinškemu uvozu iz držav, ki niso članice Evropske skupnosti [1] (v nadaljnjem besedilu: osnovna uredba), in zlasti člena 7 Uredbe,
Initiation
Začetek preiskave
On 30 June 2009, the Commission received a complaint concerning imports of dry sodium gluconate (SG) originating in the People’s Republic of China (China) lodged pursuant to Article 5 of the basic Regulation by the European Chemical Industry Council (CEFIC) (the complainant) on behalf of producers representing a major proportion, in this case more than 50 %, of the total Union production of dry sodium gluconate.
Komisija je 30. junija 2009 prejela pritožbo v zvezi z uvozom suhega natrijevega glukonata s poreklom iz Ljudske republike Kitajske („Kitajska“), ki jo je v skladu s členom 5 osnovne uredbe vložil Svet evropske kemijske industrije (CEFIC) („pritožnik“) v imenu proizvajalcev, ki predstavljajo večji delež, v tem primeru več kot 50 % celotne proizvodnje suhega natrijevega glukonata v Uniji.
The complaint contained prima facie evidence of dumping and of material injury caused by such dumping which was considered sufficient to justify the opening of an anti-dumping proceeding.
Pritožba je vsebovala prima facie dokaze o dampingu in znatni škodi, ki jo je povzročil, kar je zadostovalo za upravičenost začetka protidampinškega postopka.
On 11 August 2009, a proceeding was initiated by the publication of a notice of initiation in the Official Journal of the European Union [2].
Postopek se je začel 11. avgusta 2009 z objavo obvestila o začetku protidampinškega postopka v Uradnem listu Evropske unije [2].
The Commission officially advised the exporting producers in China, importers, traders, users and associations known to be concerned, the authorities of China and the complainant Union producers of the initiation of the proceeding.
Komisija je o začetku postopka uradno obvestila proizvajalce izvoznike na Kitajskem, uvoznike, trgovce, uporabnike in združenja, za katere je znano, da jih to zadeva, kitajske organe in proizvajalce Unije, ki so vložili pritožbo.
Interested parties were given the opportunity to make their views known in writing and to request a hearing within the time limit set in the notice of initiation.
Zainteresirane stranke so imele možnost, da v roku iz obvestila o začetku protidampinškega postopka pisno izrazijo svoja stališča in zahtevajo zaslišanje.
All interested parties who so requested and showed that there were particular reasons why they should be heard were granted a hearing.
Vsem zainteresiranim strankam, ki so zahtevale zaslišanje in dokazale, da zanj obstajajo posebni razlogi, je bilo zaslišanje odobreno.
In order to allow exporting producers to submit a claim for market economy treatment (MET) or individual treatment (IT), if they so wished, the Commission sent claim forms to the Chinese exporting producers known to be concerned and to the authorities of China.
Da bi proizvajalci izvozniki lahko predložili zahtevek za tržnogospodarsko obravnavo („TGO“) ali individualno obravnavo („IO“), če tako želijo, je Komisija kitajskim proizvajalcem izvoznikom, za katere je znano, da jih to zadeva, in kitajskim organom poslala obrazce za zahtevek.
One exporting producer requested MET pursuant to Article 2(7) of the basic Regulation and another exporting producer, including two related companies, requested IT pursuant to Article 9(5) of the same Regulation.
En proizvajalec izvoznik je zahteval TGO v skladu s členom 2(7) osnovne uredbe, drug proizvajalec izvoznik, vključno z dvema povezanima družbama, pa IO v skladu s členom 9(5) iste uredbe.
In view of the apparent high number of exporting producers in China and importers in the Union, the Commission indicated in the notice of initiation that sampling might be applied for these parties in accordance with Article 17 of the basic Regulation.
Komisija je glede na očitno veliko število kitajskih proizvajalcev izvoznikov ter uvoznikov v Uniji v obvestilu o začetku protidampinškega postopka navedla, da bo morda v skladu s členom 17 osnovne uredbe za te stranke uporabila vzorčenje.
In order to enable the Commission to decide whether sampling would be necessary and, if so, to select a sample, all exporting producers in China and Union importers were asked to make themselves known to the Commission and to provide, as specified in the notice of initiation, basic information on their activities related to the product concerned during the investigation period (1 July 2008 to 30 June 2009).
Da bi se Komisija lahko odločila, ali bo vzorčenje potrebno, in če bi bilo, izbrala vzorec, so bili vsi kitajski proizvajalci izvozniki in uvozniki v Uniji pozvani, da se javijo Komisiji in predložijo osnovne informacije o svojih dejavnostih v zvezi z zadevnim izdelkom v obdobju preiskave (od 1. julija 2008 do 30. junija 2009), kakor je določeno v obvestilu o začetku.
Given the limited number of responses to the sampling exercise, it was decided that sampling was not necessary for Chinese exporting producers or importers in the Union.
Glede na omejeno število odgovorov na vzorčenje je bilo odločeno, da vzorčenje za kitajske proizvajalce izvoznike ali uvoznike v Uniji ni potrebno.
Questionnaires were sent to all companies in China and importers in the Union who responded to the sampling exercise, to the Union producers, and to all known importers and users in the Union.
Vprašalniki so bili poslani vsem družbam na Kitajskem in uvoznikom v Uniji, ki so se odzvali na vzorčenje, proizvajalcem v Uniji ter vsem poznanim uvoznikom in uporabnikom v Uniji.
Replies were received from two exporting producers or groups of exporting producers in China, two producers in the Union and four importers/users.
Odgovore so poslali dva proizvajalca ali skupine proizvajalcev izvoznikov na Kitajskem, dva proizvajalca v Uniji in štirje uvozniki/uporabniki.